Overview of Histone Deacetylase Inhibitors in Haematological Malignancies
AbstractHistone deacetylase inhibitors (HDACi) can induce hyperacetylation of both histone and non-histone target resulting in epigenetic reprogramming and altered activity, stability and localisation of non-histone proteins to ultimately mediate diverse biological effects on cancer cells and their microenvironment. Clinical trials have demonstrated single agent HDACi to have activity in hematological malignancies, in particular T-cell lymphoma and Hodgkin lymphoma. Combination strategies with standard therapies based on pre-clinical data are being employed with significant success due to their excellent side effect profile. Correlative studies will provide valuable information on the sub-groups of patients more likely to respond or be resistant to HDACi therapy, while long-term monitoring for toxicities is also needed.
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Bishton, M.J.; Johnstone, R.W.; Dickinson, M.; Harrison, S.; Prince, H.M. Overview of Histone Deacetylase Inhibitors in Haematological Malignancies. Pharmaceuticals 2010, 3, 2674-2688.
Bishton MJ, Johnstone RW, Dickinson M, Harrison S, Prince HM. Overview of Histone Deacetylase Inhibitors in Haematological Malignancies. Pharmaceuticals. 2010; 3(8):2674-2688.Chicago/Turabian Style
Bishton, Mark J.; Johnstone, Ricky W.; Dickinson, Michael; Harrison, Simon; Prince, H. Miles. 2010. "Overview of Histone Deacetylase Inhibitors in Haematological Malignancies." Pharmaceuticals 3, no. 8: 2674-2688.